Understand the RECONNECT findings and why a specific HSDD medicine is different from a universal sexual-performance claim.
Bremelanotide is the active substance in VYLEESI and is also discussed under the research name PT-141. The US indication concerns premenopausal women with acquired, generalised hypoactive sexual desire disorder, or HSDD. The label excludes cases explained by a coexisting medical or psychiatric condition, relationship problems or a medicine or substance. That is a specific clinical framework. It should not be collapsed into the broader idea that anyone with lower interest needs a drug.
The RECONNECT publication reports two randomised, double-blind, placebo-controlled studies over 24 weeks. Together, they randomised 1,267 women with HSDD. The co-primary endpoints assessed sexual desire and distress related to low desire using specified scales. These were patient-reported outcomes, not a simple count of sexual activity. Understanding that measurement is essential: a claim about desire, distress, performance or number of encounters is not automatically a claim about the same result.
Preparing the full guide…
The extended sections are available during your one-minute preview and with free email registration.
- What the published differences mean
- Desire is different from a performance guarantee
- Longer follow-up gives information with a different design
- Benefits and unwanted effects need the same visibility
- PT-141 research does not assess every product carrying that name
- How to frame a respectful clinical question
Sources & further reading
Sources support specific statements, not every possible use of a molecule. Echo hub articles provide research background; original publications and official guidance are identified where supplied.
- FDA — VYLEESI prescribing information, revised October 2026
- Kingsberg et al. — Bremelanotide for HSDD: two randomised phase 3 RECONNECT trials (2019)
- Simon et al. — Long-term safety and efficacy: the RECONNECT open-label extension (2019)